ClinicalTrials.gg
CompletedNCT07350044PENG-FEMUpdated Nov 4, 2026

Comparison of Femoral Nerve Block and Combined PENG Plus Femoral Nerve Block in Geriatric Hip Surgery

An interventional study of Pericapsular nerve group (PENG) block plus femoral nerve block and Femoral Nerve Block in PENG Block and Hip Fracture Surgeries, sponsored by Ankara City Hospital Bilkent. Completed at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Pain by Ankara City Hospital Bilkent — 6 open to participants now, 6 under way, none of them phase 3. Pain · Ankara City Hospital Bilkent.

Enrollment
8th of 17
72 · median 70
Started
2026
with 4 others
No phase
16 of 23
3 open now
Registered
17th of 23
by date

Among the 23 studies in Pain by Ankara City Hospital Bilkent, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 with no phase, and was the 17th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 23 studies in Pain by Ankara City Hospital Bilkent are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Pain by Ankara City Hospital Bilkent, or all of them as a file.
02

Study summary

Hip fracture surgery in geriatric patients is frequently associated with severe perioperative pain, which may complicate positioning for spinal anesthesia and increase perioperative opioid requirements. Regional analgesic techniques are commonly used to improve patient comfort and reduce opioid consumption in this vulnerable population. The femoral nerve block is a well-established method for analgesia in hip surgery, while the pericapsular nerve group (PENG) block has emerged as a novel technique targeting articular branches of the hip joint with potential advantages in pain control.

This prospective randomized controlled trial aims to compare the analgesic efficacy of femoral nerve block alone versus a combined pericapsular nerve group (PENG) plus femoral nerve block in geriatric patients undergoing hip fracture surgery under spinal anesthesia. The primary outcomes include perioperative pain intensity, opioid consumption within the first 24 hours postoperatively, and the need for additional analgesia during positioning for spinal anesthesia. Secondary outcomes include spinal anesthesia procedure duration, time to sensory block onset, time to first postoperative opioid requirement, and perioperative hemodynamic parameters.

The results of this study are expected to clarify whether the addition of the PENG block to femoral nerve block provides superior perioperative analgesia and improved patient comfort compared with femoral nerve block alone in geriatric hip fracture surgery.

Read the detailed description

Hip fractures represent one of the most common orthopedic emergencies in the geriatric population and are associated with significant pain, morbidity, and mortality. Effective perioperative analgesia is essential in this fragile patient group, as inadequate pain control may contribute to delayed mobilization, increased cardiopulmonary complications, delirium, and prolonged hospital stay. Traditional opioid-based analgesic strategies are frequently associated with adverse effects such as nausea, vomiting, respiratory depression, and cognitive impairment, particularly in elderly patients. Therefore, regional anesthesia techniques have gained increasing importance in hip fracture surgery.

The hip joint has a complex sensory innervation primarily derived from the femoral, obturator, and accessory obturator nerves. The femoral nerve block is a well-established technique that provides effective analgesia for hip surgery; however, it may be associated with quadriceps muscle weakness due to motor fiber involvement, potentially delaying early mobilization. The pericapsular nerve group (PENG) block, first described in 2018, selectively targets the articular branches of the femoral, obturator, and accessory obturator nerves while largely preserving motor function. Emerging evidence suggests that the PENG block may provide effective analgesia with minimal impact on quadriceps strength.

Despite these findings, the additional analgesic benefit of combining the PENG block with the femoral nerve block remains unclear. This study is designed to evaluate whether the addition of the PENG block to a standard femoral nerve block improves perioperative analgesic outcomes in elderly patients undergoing hip surgery under spinal anesthesia.

This prospective, single-center, randomized controlled trial will be conducted at Ankara Bilkent City Hospital. A total of 68 patients aged 65 years or older, classified as American Society of Anesthesiologists (ASA) physical status I-III, and scheduled for hip surgery under spinal anesthesia will be enrolled after obtaining written informed consent. Patients will be randomly allocated into two groups: Group 1 will receive a preoperative femoral nerve block, and Group 2 will receive a combination of preoperative PENG block and femoral nerve block.

All nerve blocks will be performed approximately 30 minutes before surgery in the designated block area under standard monitoring, including electrocardiography, non-invasive blood pressure measurement, and pulse oximetry. Supplemental oxygen will be administered via nasal cannula at 2 L/min. The PENG block will be performed under ultrasound guidance using an 80-mm block needle, with 20 mL of 0.25% bupivacaine injected incrementally beneath the psoas tendon between the anterior inferior iliac spine and the iliopubic eminence. The femoral nerve block will be performed under ultrasound guidance using a 50-mm block needle, with 20 mL of 0.25% bupivacaine administered incrementally around the femoral nerve.

The time to onset of sensory block will be recorded. Pain intensity will be assessed using the Visual Analog Scale (VAS) at rest and during 15° leg elevation before block placement and 30 minutes after block administration. Hemodynamic parameters, including heart rate, oxygen saturation, and systolic, diastolic, and mean arterial blood pressure, will be recorded at the same time points.

Following block assessment, patients will be transferred to the operating room and positioned in the lateral decubitus position for spinal anesthesia, with the surgical side down. VAS scores will be reassessed during positioning. If a VAS score of 4 or greater is observed during positioning, intravenous fentanyl at a dose of 1 µg/kg will be administered as rescue analgesia. Spinal anesthesia will be performed in the lateral decubitus position using 10 mg (2 mL) of hyperbaric bupivacaine. After intrathecal injection, patients will remain in the lateral position for five minutes before being positioned for surgery.

The duration of the spinal anesthesia procedure will be recorded, including patient positioning, skin antisepsis, sterile draping, intrathecal injection, and needle removal. This approach is intended to evaluate the effect of the applied peripheral nerve blocks on patient comfort and ease of positioning for spinal anesthesia.

Intraoperatively, all patients will be continuously monitored for heart rate, oxygen saturation, electrocardiography, and non-invasive (or invasive if clinically indicated) arterial blood pressure. Postoperatively, patients will be followed in the post-anesthesia care unit for 24 hours.

Postoperative pain will be assessed using VAS at 0, 2, 8, 16, and 24 hours. The time to first analgesic request, total opioid consumption within the first 24 hours, and hemodynamic parameters will be recorded. Postoperative analgesia will be standardized for all patients: intravenous paracetamol 1 g every 6 hours (maximum 4 g/day, or 3 g/day in elderly patients or those with hepatic impairment). If VAS exceeds 4 despite paracetamol administration, intravenous tramadol 50 mg will be administered as rescue analgesia, with a maximum daily dose of 300 mg. Patients will be closely monitored for opioid-related adverse effects, including sedation, nausea, vomiting, and cardiorespiratory complications.

The primary outcome of the study is the comparison of postoperative analgesic efficacy between the femoral nerve block alone and the combined PENG plus femoral nerve block, as assessed by VAS scores and opioid consumption during the first 24 hours. Secondary outcomes include intraoperative and postoperative hemodynamic stability, time to sensory block onset, ease and duration of spinal anesthesia performance, patient comfort during positioning, and time to first postoperative analgesic requirement.

The results of this study are expected to provide valuable evidence regarding the optimal regional anesthesia strategy for perioperative pain management in geriatric hip surgery patients and to contribute to improved analgesic protocols with reduced opioid exposure.

03

Conditions studied

  • PENG Block
  • Hip Fracture Surgeries

Browse trials for

Keywords

  • PENG block
  • Femoral block
  • Hip Fracture Surgeries
  • Pain
  • Opioid
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years and older,
  • Patients scheduled for surgery due to hip fracture,
  • (ASA) physical status I-III,
  • between 18 and 40 kg/m²,
  • Preoperative fasting duration of approximately 8 hours,
  • Planned spinal anesthesia,
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Age below 65 years,
  • Refusal to participate in the study,
  • Severe cognitive impairment, dementia, or Alzheimer's disease,
  • IV or higher,
  • > 40 kg/m²,
  • Failed spinal anesthesia or conversion to general anesthesia,
  • Revision hip surgery,
  • Multiple trauma patients,
  • Old hip fractures (>3 weeks),
  • Active receiving chemotherapy or radiotherapy,
  • Active infection requiring antibiotic treatment (except prophylaxis),
  • to regional anesthesia techniques,
  • Chronic or therapy,
  • Use of anti-inflammatory drugs,
  • Non-fasted patients,
  • Allergy or intolerance to local anesthetics, paracetamol, tramadol, or other opioids.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Femoral Nerve Block

    Participants will receive a preoperative ultrasound-guided femoral nerve block performed approximately 30 minutes before surgery.

    Procedure: Femoral Nerve Block

  • Experimental
    PENG Block + Femoral Nerve Block

    Participants will receive a combination of preoperative ultrasound-guided pericapsular nerve group (PENG) block and femoral nerve block performed approximately 30 minutes before surgery.

    Procedure: Pericapsular nerve group (PENG) block plus femoral nerve block

Interventions

  • ProcedurePericapsular nerve group (PENG) block plus femoral nerve block

    Combination of ultrasound-guided pericapsular nerve group (PENG) block and femoral nerve block performed preoperatively approximately 30 minutes before surgery using 20 mL of 0.25% bupivacaine for each block for perioperative analgesia.

  • ProcedureFemoral Nerve Block

    Ultrasound-guided femoral nerve block performed preoperatively approximately 30 minutes before surgery using 20 mL of 0.25% bupivacaine for perioperative analgesia.

06

What researchers measure

Primary outcomes

  1. Pain Score During Positioning for Spinal Anesthesia

    To compare pain intensity during patient positioning for spinal anesthesia between the Femoral Nerve Block group and the combined Pericapsular Nerve Group (PENG) + Femoral Nerve Block group. Pain will be assessed using the Visual Analog Scale (VAS) at the time of lateral decubitus positioning for spinal anesthesia. The need for additional intravenous fentanyl during positioning will also be recorded.

    Time frame: Periprocedural: from initiation of lateral decubitus positioning for spinal anesthesia to completion of the spinal anesthetic procedure (needle withdrawal following intrathecal injection).

Secondary outcomes

  1. Postoperative Pain Scores Within the First 24 Hours

    To compare postoperative pain intensity between the Femoral Nerve Block group and the combined Pericapsular Nerve Group (PENG) + Femoral Nerve Block group using the Visual Analog Scale (VAS). Pain scores will be assessed at rest and during movement at postoperative 0, 2, 8, 16, and 24 hours.

    Time frame: Within the first 24 hours postoperatively

  2. Total Opioid Consumption Within the First 24 Hours

    To compare total intravenous opioid consumption between groups within the first 24 postoperative hours. Opioid use will be recorded as cumulative tramadol consumption (mg) administered as rescue analgesia.

    Time frame: Within the first 24 hours postoperatively.

  3. Hemodynamic Stability During Perioperative Period

    To compare perioperative hemodynamic parameters including heart rate, systolic, diastolic, and mean arterial blood pressure, and peripheral oxygen saturation (SpO₂) between groups during the block procedure, intraoperative period, and the first 24 postoperative hours.

    Time frame: From block application to 24 hours postoperatively

07

Study locations

1 site
  • Ankara Bilkent City Hospital
    Ankara, Turkey (Türkiye)
08

References and documents

Publications

  • 39514540
  • 38073453
  • PMID: 38073453

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Jun 2026, 3 months.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 3 months is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Jan 2026 → Feb 2026 and primary completion May 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 20, 2026
StartActual
Feb 25, 2026was Jan 2026
Primary completionActual
Jun 1, 2026was May 2026
CompletionActual
Jun 1, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 15, 2026→Feb 25, 2026
Nov 4, 2026
Primary completion
May 15, 2026→Jun 1, 2026
Nov 4, 2026
Enrollment
68→72
Sep 29, 2026
Show all 2 updates
  1. Nov 4, 2026
    Start date Jan 15, 2026→Feb 25, 2026
    Primary completion May 15, 2026→Jun 1, 2026
  2. Sep 29, 2026
    Enrollment 68→72
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07350044
Responsible party
semih başkan (MD, Clinical Professor, Anesthesiology and Reanimation, Principal İnvestigator, Ankara Bilkent Sehir Hastanesi) — Principal investigator
First posted
Jan 20, 2026
Start date
Feb 25, 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion